The cost of drug development for Alzehimer’s Disease
No surprise, but it’s high. Chandra, Coile and Mommaerts (2023) write: The average cost of AD [Alzheimer’s Disease] drug development is estimated (based on a host of assumptions) to be $5.6 billion, largely due to high preclinical and phase 3 trial costs (Cummings, Reiber, and Kumar 2018). This number greatly exceeds R&D costs for other…